BRIGADE-M3-EUROPEAN
30.4.2022 03:34:12 CEST | Business Wire | Press release
Brigade-M3 European Acquisition Corp. (the “Company ”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, announces that the Company's Annual Report for the period from its incorporation to 31 December 2021 (“Annual Report ”), which was due by 30 April 2022, will be subject to a short delay due to the fact that the audit of the annual accounts by the Company’s auditor, KPMG, will not be completed in time.
The Board of Directors of the Company has not been made aware of any material audit matters which remain outstanding.
The Annual Report will be published as soon as practically possible following the conclusion of the audit process.
IMPORTANT INFORMATION
This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
DISCLAIMER
This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public or form of application to subscribe for securities.
The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions. No action has been taken by the Company that would permit an offer of securities or the possession or distribution of this announcement or any other offering or publicity material relating to such securities in any jurisdiction where action for that purpose is required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 13:24:00 CEST | Press release
The installation marks a significant step in the evolution of premium No/Low wines, where preserving aroma and sensory quality has become a defining industry priority. Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking exper
Croma-Pharma Expands Its Portfolio in Canada With saypha® lips Lidocaine and Exprecell™5.10.2026 13:12:00 CEST | Press release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
Anaeco Secures Strategic Investment from Momentum Global Ventures to Accelerate Commercial Deployment5.10.2026 12:00:00 CEST | Press release
Investment supports commercialization across anesthetics, refrigerants, and semiconductor manufacturing Anaeco, Inc., a clean technology company developing systems to destroy harmful and difficult-to-abate gases, today announced a strategic investment from Momentum Global Ventures. The investment supports Anaeco as it moves from technology development and validation to commercial deployment across three initial markets: anesthetic gases, refrigerants, and semiconductor manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005546122/en/ Anaeco’s technology exploits atmospheric chemistry to destroy harmful, high-impact gases, including HFCs, PFAS, anesthetic gases, N2O, and other difficult-to-abate emissions at their source. By accelerating processes that naturally transform pollutants, its modular technology provides a practical, scalable approach to emissions that are difficult or costly to manage conventionally.
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform with the Addition of MOSS EOS for Early Onset Scoliosis Surgery5.10.2026 11:00:00 CEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the selective market introduction of the MOSS EOS® System for the treatment of children with severe early onset scoliosis.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005092768/en/ Early Onset Scoliosis is a rare pediatric disease where in certain cases surgical intervention can be indicated.2 Breaking new ground, Biedermann Motech will now introduce the world’s first MOSS EOS System featuring MOSS!MODULARITY™ to selective markets outside the U.S. The MOSS EOS System encompasses a modular platform of products and technologies for growth friendly pediatric spinal deformity surgery. Prof. Dr. Heiko Koller from Germany, one of the innovators behind the MOSS EOS System, carried out the first surgeries. His feedback was that the versatility of the system offers surgeons a broad range
LTM Launches BlueVerse™ AgenTraceIQ5.10.2026 10:30:00 CEST | Press release
Offering stems from Rubrik’s Project Hourglass, an alliance helping organizations scale agentic AI securely LTM, the Business Creativity partner to the world's largest enterprises, today announced the launch of BlueVerse™ AgenTraceIQ, an offering designed to help organizations securely adopt and scale agentic AI. Combining Rubrik Agent Cloud with LTM's AI governance and managed services expertise, the offering enables organizations to monitor AI agents, establish guardrails, and rewind unintended agent actions across business-critical environments. Aspart of Rubrik’s Project Hourglass, LTM and other elite Global Systems Integrators partner with Rubrik, the Security and AI Operations Company, to deliver Rubrik Agent Cloud for Anthropic's Claude Code to their enterprise clients. The collaboration strengthens the ability for organizations to adopt agentic systems with the necessary security, governance, and resilience at scale. "As AI agents increasingly act autonomously, the stakes for e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom